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ABSTRACT 
THE CLINICAL AND MOLECULAR CHARACTERIZATION OF 
EXTENSIVELY DRUG RESISTANT (XDR) ACINETOBACTER BAUMANNII 
COMPLEX FROM CLINICAL ISOLATES IN HOSPITAL RAJA PEREMPUAN 
ZAINAB II 
Introduction: Acinetobacter baumannii (A. baumannii) is an important cause of 
hospital-acquired infections. However, treating these infections is a challenge due to the 
isolation of multiply drug resistant strains that has limited antibiotic susceptibility. This 
study aims to consider the molecular characteristics of the XDR A. baumannii, the 
clinical characteristics of patients who are treated for the bacterial infection and 
recognize factors associated with poor treatment outcome.  
Methodology: A cross sectional study was conducted among patients from which XDR 
A. baumannii were isolated from 1
st
 January 2016 to 30
th
 April 2017 in Hospital Raja 
Perempuan Zainab II. The isolates from non-repeat clinical samples which show 
extensive drug resistance pattern were collected and their species identification were 
confirmed using Vitek 2®. These isolates were then subjected to multiplex PCR 
analysis for the detection of oxacillinases resistance genes, namely blaOXA-51-like, blaOXA-
23-like, blaOXA-24-like and blaOXA-58-like. Patients’ records of infective cases were reviewed 
for demographic data and clinical characteristics. These data were analysed using 
multiple logistic regression to identify variables that lead to end-of-treatment mortality 
among patients who were infected with XDR A. baumannii.   
Results: XDR A. baumannii were isolated from 116 patients, and 65 of these cases 
were considered infectives and were treated for their XDR A. baumannii infection. All 
the isolates harboured the blaOXA-51-like gene, while the blaOXA-23-like were detected in all 
xiii 
 
isolates but two. Most of the isolates regarded as clinically significant are from tracheal 
aspirate (45 samples), followed by blood (9 samples) and the remaining are from urine, 
tissue and pus (11 samples). Among those who are treated, the end-of-treatment 
mortality rate was 60.0% (39 patients). Repeat cultures after 72-hour of treatment were 
obtained from 31 of the infected patients, with 35.5% (11 patients) achieving 
microbiological eradication, 6.5% (2 patients) having microbiological noneradication 
while the majority (58.1%; 18 patients) having breakthrough infection. In the 
multivariable analysis, presence of sepsis (adjusted odds ratio (aOR) 7.93; 95% 
confidence interval (CI) 1.45, 43.26; p-value = 0.017) and presence of arterial catheter 
(aOR 15.53; CI 1.66, 145.71; p-value = 0.016) were independently associated with 
increased risk of end-of-treatment mortality. Conversely, longer treatment duration with 
polymyxin (aOR 0.71; CI 0.588, 0.856; p-value <0.001) was associated with decreased 
risk of end-of-treatment mortality.  
Conclusions: Most of the XDR A. baumannii isolates in this study harboured the 
blaOXA-51-like gene and the blaOXA-23-like. Almost half of the isolates were considered 
clinically significant. Among patients who are treated for XDR Acinetobacter 
baumannii infection, presence of sepsis and presence of arterial catheter significantly 
increased risk of mortality. Yet, the risk for end-of-treatment mortality may be reduced 
with longer duration of colistin therapy. 
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ABSTRAK 
CIRI-CIRI MOLEKULAR DAN KLINIKAL ACINETOBACTER BAUMANNI 
KERINTANGAN ANTIBIOTIK MENYELURUH (XDR) DARIPADA SAMPEL 
KLINIKAL DARI HOSPITAL RAJA PEREMPUAN ZAINAB II 
Pengenalan: Acinetobacter baumannii ialah salah satu bakteria penyebab utama 
jangkitan yang diperolehi semasa menerima rawatan di hospital. Walaupun begitu, 
merawat jangkitan ini kini menjadi semakin sukar disebabkan kewujudan bakteria 
rintang pelbagai antibiotik yang mempunyai tahap kepekaan antibiotik yang terhad. 
Kajian ini bertujuan untuk mengenalpasti ciri-ciri molekular Acinetobacter baumanni 
kerintangan antibiotik menyeluruh (XDR), ciri-ciri klinikal pesakit yang dijangkiti 
bakteria ini dan faktor-faktor yang berkaitan dengan kesudahan tidak baik setelah 
rawatan. 
Tatacara Kajian: Satu kajian keratan rentas telah dijalankan di kalangan pesakit yang 
didapati mempunyai XDR A. baumannii dari sampel klinikal bermula 1 Januari 2016 
sehingga 30 April 2017 di Hospital Raja Perempuan Zainab II. Bakteria daripada 
sampel klinikal bukan-berulang yang menunjukkan corak kerintangan antibiotik 
menyeluruh dikutip dan pengenalan spesis dilakukan menggunakan Vitek 2®. Bakteria 
ini kemudiannya dianalisa menggunakan PCR multipleks untuk mengesan gen 
kerintangan oxacillinases, iaitu blaOXA-51-like, blaOXA-23-like, blaOXA-24-like dan blaOXA-58-like. 
Rekod pesakit-pesakit yang dijangkiti disemak untuk mendapatkan maklumat 
demografik dan klinikal. Maklumat ini dianalisa menggunakan logistik regresi berganda 
bagi mengenalpasti penentu yang berkaitan dengan mortaliti setelah rawatan bagi 
pesakit yang dijangkiti XDR A. baumannii. 
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Keputusan: XDR A. baumannii ditemui daripada 116 pesakit, dan 65 daripada pesakit 
ini dijangkiti dan dirawat untuk jangkitan XDR A. baumannii. Kesemua bakteria 
tersebut didapati mempunyai gen blaOXA-51-like, dan blaOXA-23-like turut dikesan pada 
hampir kesemua bakteria kecuali dua. Kebanyakan bakteria yang dianggap signifikan 
dari segi klinikal dijumpai dari sampel cecair trakea (45 sampel), diikuti dengan sampel 
darah (9 sampel) dan yang lainnya daripada sampel air kencing, tisu dan nanah (11 
sampel). Di kalangan mereka yang dirawat, mortaliti setelah rawatan adalah sebanyak 
60% (39 pesakit). Kultur ulangan setelah 72 jam menerima rawatan diperolehi daripada 
31 orang pesakit yang dijangkiti, dengan 35.5% (11 pesakit) berjaya mencapai 
pembasmian mikrobiologi, 6.5% (2 pesakit) gagal mencapai pembasmian mikrobiologi 
manakala majoriti (58.1%; 18 pesakit) mendapat jangkitan sampingan. Daripada analisa 
logistik regresi berganda, keadaan sepsis (nisbah kemungkinan terlaras (aOR) 7.93; 
julat keyakinan 95% (CI) 1.45, 43.26; nilai p = 0.017) dan kewujudan kateter arteri 
(aOR 15.53; CI 1.66, 145.71; nilai p = 0.016) dikaitkan secara bebas dengan 
peningkatan risiko mortaliti setelah rawatan. Tetapi, jangka masa rawatan dengan 
polymyxin yang lebih lama (aOR 0.7I; CI 0.588, 0.856; nilai p <0.001) dikaitkan dengan 
pengurangan risiko mortaliti setelah rawatan. 
Kesimpulan: Kebanyakan XDR A. baumannii dalam kajian ini mengandungi gen 
blaOXA-51-like dan blaOXA-23-like. Hampir separuh daripada bakteria yang dikutip dianggap 
signifikan dari segi klinikal. Di kalangan pesakit yang dirawat untuk jangkitan XDR A. 
baumannii, keadaan sepsis dan kewujudan kateter arteri meningkatkan risiko mortaliti 
secara signifikan. Walau bagaimanapun, risiko mortaliti setalah rawatan dapat 
dikurangkan dengan jangka masa rawatan polymyxin yang lebih lama. 
 
1 
 
1 Introduction 
1.1 Nomenclature of Acinetobacter spp. 
The first account of Acinetobacter spp. was in 1911 when a Dutch 
microbiologist describe an organism named Micrococcus calco-aceticus isolated from 
soil in a calcium-acetate-containing minimal medium (Beijerinck, 1911). Since then, 
similar organisms had been described and allocated to at least 15 distinct genera and 
species until the current genus Acinetobacter was proposed by Brisou and Prevot in 
1954. The genus became widely accepted in 1968 after a survey by Baumann et al. 
showed that all the different species belonged to the Acinetobacter genus (Baumann et 
al., 1968). Currently, the genus comprises of Gram-negative, non-fermenting, strictly 
aerobic, non-fastidious, non-motile, catalase-positive, oxidase-negative bacteria with a 
DNA G+C content of 39% to 47%. Another significant discovery in the Acinetobacter 
genus was achieved in 1986 by Bouvet and Grimont when they successfully 
distinguished 12 genospecies via DNA-DNA hybridization studies (Bouvet and 
Grimont, 1986). Some of these species were given formal species names, including A. 
baumannii (genomic species 2), A. calcoaceticus (genomic species 1), A. haemolyticus 
(genomic species 4), A. johnsonii (genomic species 7), A. junii (genomic species 5), and 
A. lwoffi (genomic species 8/9). Acinetobacter genomic species 3 and genomic species 
13TU were later formally named as A. pittii and A. nosocomialis (Nemec et al., 2011). 
With the advent of molecular techniques, increasing number of distinct species within 
the Acinetobacter genus had been identified and 55 species had been named as of July 
2017 (Parte, 2017).  
A. calcoaceticus, A. baumannii, A. pittii, and A. nosocomialis are interrelated 
and cannot be distinguished from one another by phenotypic characteristics, thus it has 
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been proposed to refer to these species as the A. calcoaceticus-A. baumannii complex 
(Gerner-Smidt et al., 1991). Another species had been recently identified among this 
complex: A. seifertii (Nemec et al., 2015) and a provisional genomospecies called 
“between 1 & 3’. The problem with grouping these species together is that not all of 
them are clinically significant.  A. baumannii, A. pittii, A. nosocomialis and A. seifertii 
are considered significant and had been implicated in human infections, but A. 
calcoaceticus is ubiquitous in soil and water and rarely been associated with serious 
clinical disease. This highlighted the need to distinguish between the Acinetobacter sp. 
within A. baumannii complex because these species differ in term of infectious 
potential, antimicrobial susceptibility and mortality rates, hence precise identification 
can guide therapy and limit unnecessary treatment of non-pathogenic strains.  
1.2 Epidemiology 
Acinetobacter spp. was initially regarded as a commensal opportunist, a 
pathogen of low virulence with minimal significance. However, the increasing use of 
complex invasive medical intervention in the last few decades had caused a surge in the 
frequency and severity of Acinetobacter infection. In the United States, data from the 
National Healthcare Safety Network (NHSN) from 2011 to 2014 showed Acinetobacter 
spp. accounted for 1.07% of the total isolates that cause healthcare-associated infection 
(HAI), with multidrug resistant strains accounting for 33-75% of the isolates, depending 
on samples (Weiner et al., 2016). Data from European Centre for Disease Prevention 
and Control (ECDC) which conducted surveillance on HAI in intensive care units (ICU) 
in Europe in 2014 found that Acinetobacter spp. accounted for 2.5% and 1.6% of blood 
stream infection and urinary tract infection, respectively (ECDC, 2016), with 
carbapenem-resistance detected in 63.5% of A. baumannii isolates. In comparison, 
Acinetobacter spp. cause a much higher proportion of HCAI in developing countries 
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and may become the principal nosocomial pathogen. In South America, Acinetobacter 
spp. was the most prevalent isolate encountered from ICU patients with HCAI 
especially ventilator-associated pneumonia (VAP). It was responsible for up to 31% of 
the total isolates and the carbapenem resistance ranged from 56 to 76% (Luna et al., 
2014). Data from Africa showed that Acinetobacter spp. accounts for about 14.8% of 
ICU infections (Vincent et al., 2009).   
In the Southeast Asia region, the prevalence of carbapenem-resistant 
Acinetobacter baumannii (CRAB) ranges from 25% to 90.5% (Kiratisin et al., 2012). In 
Malaysia, the rate of CRAB in 2016 was 60% (unpublished National Antibiotic 
Surveillance report 2016). The high prevalence of carbapenem resistance amongst 
important nosocomial pathogens warrants rigorous infection control measures and 
appropriate antimicrobial use in the Southeast Asia region. 
1.3 Transmission 
 Acinetobacter spp. intrinsic resistance to desiccation leads to its environmental 
tenacity and high transmissibility. The pathogen thrives in hot and humid tropical 
climates, which may explain the high prevalence seen in hot and tropical countries (i.e. 
Africa, South America). Cases also show seasonal predilection; the rate of 
Acinetobacter infections in the United States increased by 54% between July and 
October compared to November through June (McDonald et al., 1999). 
       In the healthcare setting, it is established that Acinetobacter spp. is 
transmitted to patients through transient colonization of the hands of the health care 
workers and persistence on environmental surfaces (Russotto et al., 2015). Studies had 
also shown that the pathogen can be spread via aerosolization from infected and 
colonized patients (Spellberg and Bonomo, 2013). These aerosolized bacteria may 
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survive up to several weeks in the air (Yakupogullari et al., 2016). However, a study 
had found that the frequency of air contamination by A. baumannii is variable. Factors 
that could reduce the rate of air contamination include the use of closed circuit 
mechanical ventilation system, frequent air exchanges and the bacterial burden of the 
patient, which may be low if the patient was treated with appropriate antibiotic (Rock et 
al., 2015). The findings that suggest Acinetobacter could be transmitted via airborne 
route implicate that current practice of cleaning environmental surfaces episodically to 
prevent spread might not be sufficient. Efforts should also be made to disinfect the air in 
patients’ rooms to ensure that the risk of transmission is reduced. 
1.4 Pathogenesis 
1.4.1 Virulence Factors 
A. baumannii intrinsically has more human virulence potential than other 
Acinetobacter spp.; it grew better at 37°C and was better able to resist macrophage 
uptake compared to other species (Tayabali et al., 2012). Even in the clinical context, a 
case-control study had shown that patients with A. baumannii bacteraemia has a higher 
28-day mortality (37% vs 6%) than those with A. ursingii bacteraemia, even though 
multidrug resistance and inadequate initial therapy were as likely to occur in patients 
infected with either species (Chiu et al., 2015). 
Under dry conditions, A. baumannii adapts morphological changes such as 
thicker cell walls which may be a factor for its persistence on environmental surfaces 
(Houang et al., 1998). Another important factor in the pathogen ability to resist 
desiccation is the Rec A enzyme which also mediates bacterial DNA repair and prevents 
its killing inside macrophages, thus contributing to its lethality in mice infection model 
(Aranda et al., 2011). Acinetobacter sp. is resistant to disinfection, too; a study had 
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shown that the presence of ethanol alters its cell physiology, enabling Acinetobacter 
species to withstand the toxic effects of salt and allowing growth on culture media 
(Smith et al., 2004). Apart from that, the presence of ethanol increased the production 
of proteins involved in lipid and carbohydrate anabolism and this correlates with 
increased carbohydrate biofilm content, enhanced biofilm formation on abiotic surfaces 
and decrease bacterial motility on semi-solid surfaces (Nwugo et al., 2012).  
The capsule of A. baumannii plays a key role in the defence of the pathogen and 
its virulence.  The K1 capsular polysaccharide-positive strains showed optimal growth 
in human ascites fluid and human serum as compared to capsule-negative strains, 
suggesting the protective role the capsule plays against complement-mediated 
destruction, opsonization and phagocytic uptake (Russo et al., 2010). Another study had 
also shown that exposure to antibiotics leads to hyperproduction of the capsular 
polysaccharide which in turn causes increased resistance to killing by host complement 
and increased virulence in a mouse model of systemic infection (Geisinger and Isberg, 
2015). Glycoproteomic data revealed prevalence of O-linked glycoproteins, which is 
required for protein glycosylation and capsular polysaccahride production in A. 
baumannii. The O-linked glycosylation favors short (three to five residue) glycans with 
limited branching containing negatively charged sugars (Scott et al., 2014). 
One of the bacterial protein that has been widely implicated in the virulence of 
A. baumannii is the outer membrane protein A (OmpA). OmpA is the most abundant 
surface protein of the bacteria and study had shown that this protein binds to eukaryotic 
cells and translocates to the nucleus by a novel monopartite nuclear localization signal 
(NLS). This nuclear translocation induces cell cytotoxicity in vitro (Choi et al., 2008). 
OmpA also plays a vital role in the pathogen ability to evade host’s complement attack 
by binding factor H from human serum, thus regulating the alternative complement 
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pathway (Kim et al., 2009).  Acinetobacter nosocomialis, another species within the A. 
baumannii complex, also employed OmpA in its pathogenesis. Mutant strain of A. 
nosocomialis which are devoid of OmpA showed reduced adherence to A549 (human 
lung carcinoma) cells, which suggest that the protein played a significant role in 
bacterial adhesion to host epithelial cells (Kim et al., 2016a). In a lethal model of 
infection of A. baumannii pneumonia, transposon-mediated disruption of OmpA 
decreased mortality in the experimental mice, suggesting a virulence function of the 
OmpA (Schweppe et al., 2015). 
The lipopolysaccharides (LPS) (endotoxin) has a major impact on Acinetobacter 
spp. virulence, inducing inflammatory cytokines such as interleukin-8 (IL-8) and 
tumour necrosis factor (TNF) from human monocytes equivalent to the levels of 
Escherichia coli stimulation. The stimulation was achieved via Toll-like receptor 4 
(TLR-4) signalling (Erridge et al., 2007a). It has also been shown that inhibition of LPS 
production via LpxC inhibitor (which affects lipid A biosynthesis) did not hinder the 
growth of the bacteria but reduce its virulence due to reduction of LPS-mediated 
activation of TLR-4, thus reducing inflammation and protecting the host from lethal 
infection (Lin et al., 2012). However, another study had shown that mutation in lpxC 
clearly diminished the in vitro growth rate of the bacteria and attenuated its infection in 
the mouse models (Beceiro et al., 2014). 
1.4.2 Immunological Defence Mechanisms  
The innate immune mechanism plays a vital role against Acinetobacter 
infection. A research on the immune response of mice intranasally inoculated with A. 
baumannii revealed that neutrophils were rapidly recruited to the lungs and declined to 
baseline levels upon clearance of the infection. Conversely, in a neutrophil-depleted 
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model of infection, there was enhancement of bacterial burden in the lungs with 
extrapulmonary bacterial dissemination (van Faassen et al., 2007). Similar observation 
was made when nonlethal inoculum of clinical A. baumannii was administered 
intraperitoneally into mice that had been pre-treated with antineutrophil antibodies. The 
infection became rapidly lethal in the absence of neutrophils (Breslow et al., 2011). 
These findings highlight the importance of neutrophils in early host defence against A. 
baumannii. 
 Macrophages also play an important part in the early, innate host defence. 
Macrophages efficiently phagocytosed and killed A. baumannii to limit their initial 
replication, released proinflammatory cytokines and recruited other cells of the innate 
immune system such as neutrophils (Qiu et al., 2012). In another research, the loss of 
Fus1, a tumour suppressor protein with immunoregulatory function resulted in an earlier 
and more robust recruitment of neutrophils and macrophages in the lungs of mice 
infected with A. baumannii with concomitant increase in phagocytosis and clearance of 
the bacteria (Hood et al., 2013). It can be concluded that neutrophils and macrophages 
are vital in the initial stages of the host immune defence to lower bacterial density, thus 
preventing the infection from becoming lethal.  
 TLR4 on immune cells had been implicated as the surface protein that was 
stimulated by A. baumannii endotoxin LPS. TLR4 gene-deficient mice was unable to 
mount the normal pulmonary chemokine/cytokine response post-intranasal infection, 
resulting in delayed onset of lung inflammation and increased bacterial count (Knapp et 
al., 2006). Similar findings were demonstrated in mice injected with turpentine to 
suppress the chemokine/cytokine response. These intranasally infected mice also 
showed reduced clearance of A. baumannii, however they sustained less host damage 
due to the dampen inflammatory chemokine response. Thus, this suggest that host 
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outcome is not only dependent on bacterial density, but also the level of host 
inflammatory response towards A. baumannii. 
 The importance of interaction between host innate immune system and bacterial 
virulence in predicting outcome is further corroborated in a study by Bruhn et al. In this 
study, strains of differing virulence were evaluated in the intravenous infection model of 
immunocompetent mice (Bruhn et al., 2015). Hypervirulent A. baumannii strains 
sustained high blood bacterial densities (>10
7
 CFU/ml) at one-hour postinfection, which 
was maintained up to 24 hours. The hypervirulent strain was also better at evading 
complement-mediated killing and macrophage uptake compared to virulent and 
avirulent strains. The virulent strain achieved 1000-fold lower bacterial densities at one-
hour postinfection and was only minimally cleared over the subsequent 23 hours. The 
avirulent strain had similar bacterial density to virulent strain at one-hour postinfection, 
and underwent an additional 100-fold decrease by 24-hour post infection due to its 
susceptibility to macrophage uptake and complement-mediated killing (Bruhn et al., 
2015).   
 A corresponding 10- to 100-fold increase of blood bacterial density of the 
avirulent strain can be seen when the mice were depleted of either macrophages, 
complement or neutrophils. Depletion of two of the immune effectors compounded the 
increase in blood bacterial density, while depletion of all three effectors synergistically 
increase the blood bacterial density to the level comparable to the hypervirulent strain. 
The blood bacterial densities of each strain at one-hour postinfection predicted lethality 
of infection (Bruhn et al., 2015). Similar finding had been demonstrated in another 
study which use an A. baumannii murine wound model. In this study, neutrophil 
depletion lead to enhancement of bacterial burden, reduction of wound healing and 
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alteration of pro-inflammatory cytokine release resulting in severe microbial disease 
(Grguric-Smith et al., 2015).  
 In summary, once inside the host, A. baumannii pathogenicity is initiated by its 
ability to escape complement and phagocytosis via its capsular composition. An early 
high load of infectious inoculum and reduction of host innate effectors, namely 
neutrophils and macrophages, also help the pathogen in escaping the host defence 
mechanism. Further damage to the host was attained by the pathogen’s LPS triggering 
of TLR-4 mediated sepsis. The understanding of Acinetobacter spp. pathogenesis 
highlights the need for early effective therapy that could prevent high bacterial densities 
in blood and tissues, thus enabling the host to clear the pathogen rapidly and avoiding 
successive host damage from sepsis response. 
1.5 Antibiotic Resistance  
 Antibiotic resistance is not a traditional virulence factor of Acinetobacter sp., 
however it is certainly the most important determinant of clinical outcome. Resistance is 
the main challenge of treating Acinetobacter infections since it limits the choice of 
antibiotics available to kill the infecting strain. Furthermore, A. baumannii is one of 
several Gram-negative species that commonly demonstrates an extensively drug 
resistance (XDR) phenotype, defined as Acinetobacter sp. isolate that is resistant to 
penicillins, cephalosporins, fluroquinolones and aminoglycosides (the multidrug 
resistant definition) and also resistant to carbapenems (Manchanda et al., 2010). 
Infections by carbapenem-resistant strains had been shown to cause greater mortality 
and prolonged hospitalization compared to carbapenem-susceptible strains (Esterly et 
al., 2011). 
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 A. baumannii has a large resistance island within its genome, which contain 45 
resistance genes (Adams et al., 2008). Additionally, it can rapidly acquire other genetic 
entities for resistance from other bacterial species (Blackwell et al., 2016) and develop 
antibiotic resistance in the middle of the course of therapy (Cheng et al., 2015). The 
mechanisms of resistance of A. baumannii can be broadly categorized as enzymatic 
mechanisms; which is the most prevalent mechanism of β-lactam resistance in A. 
baumannii, and non-enzymatic mechanisms. 
1.5.1 Enzymatic Mechanisms of Resistance 
 Enzymatic degradation by β-lactamases result in resistance towards β-lactams 
antibiotics. However, due to the complex nature of the pathogen, the interplay of 
multiple differing mechanisms may produce the same phenotype.  
1.5.1.1 Cephalosporinases and Extended Spectrum β-Lactamases (ESBL) 
All A. baumannii strains are inherently encoded with AmpC cephalosporinases 
gene in their chromosomes, also known as Acinetobacter-derived cephalosporinases 
(Hujer et al., 2005). Overexpression of this enzyme in A. baumannii is determined by 
the presence of an upstream insertion sequence (IS) element known as ISAba1. Presence 
of this element highly correlates with augmented AmpC gene expression and resistant 
to extended-spectrum cephalosporin (Corvec et al., 2003). Nevertheless, cefepime and 
carbapenems is stable in response to these enzymes. ESBL from the Ambler class A 
group have also been detected in A. baumannii. The ESBL that had been implicated 
include VEB-1, PER-1 and -2 (Farajnia et al., 2013), TEM-92 and -116, SHV-12 
(Naiemi et al., 2005) and CTX-M-2 and -43 (Celenza et al., 2006).   
1.5.1.2 Oxacillinases 
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Carbapenemases which are present in A. baumannii include the serine 
oxacillinases (Ambler class D OXA type) and the metallo-β-lactamases (Ambler class 
B). The first identified OXA-type enzyme with carbapenem-hydrolyzing activity was 
detected from a clinical strain in 1985 and was initially named ARI-1 (Paton et al., 
1993). The enzyme was derived from a plasmid-based resistance gene which was found 
to be transferable and conferred resistant towards imipenem. The gene was later 
sequenced and named blaOXA-23 (Donald et al., 2000). OXA-27 and OXA-49 are two 
other closely related enzymes that make up the blaOXA-23 gene cluster in A. baumannii. 
Subsequently, other OXA-type gene clusters with carbapenemases activity have been 
described, including the blaOXA-24-like (can be chromosomal or plasmid based) which 
encodes for OXA-24, -25, -26 and -40, and plasmid-based blaOXA-58-like which encodes 
for OXA-58. The final gene cluster and the most prevalent is the blaOXA-51-like which 
encodes for OXA-51, -64, -65, -66, -68, -69, -70, -71, -78, -79, -80 and -82. The gene 
cluster is intrinsic to A. baumannii and chromosomally based.  
The presence of the plasmid-based oxacillinases had been shown to contribute 
significantly to the carbapenem-hydrolysing capacity of A. baumannii (Héritier et al., 
2005). Similar to the ADC, expression of these OXA-type gene clusters in A. baumannii 
is dependent on the presence of insertion sequences such as ISAba1 and ISAba3 laying 
upstream to the gene clusters. For the chromosomally-encoded blaOXA-51-like gene, only 
isolates with ISAba1 adjacent to the blaOXA-51-like gene were carbapenem resistance 
(Turton et al., 2006a). The IS elements are mobile since they encode a transposase and 
they also contain promoter regions that lead to overexpression of downstream resistance 
genes. 
 Surveillance study of A. baumannii strains from the Asian regions showed that 
the blaOXA-51-like were detected in all strains. Among the plasmid-mediated 
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oxacillinases, blaOXA-23-like was the most prevalent and had been detected from almost 
all Asian countries (Kim et al., 2013). The study also found blaOXA-24-like in Taiwan 
while blaOXA-58-like was not found in any of the strains. Worldwide, A. baumannii 
strains containing blaOXA-24-like had been discovered in Spain, Belgium, China, South 
Korea and Bahrain (Poirel et al., 2010) while blaOXA-58-like had been detected in strains 
from France, United Kingdom, Argentina and Kuwait (Coelho et al., 2006).  
1.5.1.3 Metallo-β-lactamases (MBLs) 
A. baumannii also possesses MBLs (Ambler class B). Even though they are less 
prevalent compared to serine oxacillinases in the organism, these MBLs have a more 
potent hydrolytic activity (100 – 1000-fold) towards carbapenems compared to the 
OXA-type carbapenemases (Poirel and Nordmann, 2006). MBLs can hydrolyse all β-
lactam except aztreonam. All the MBLs (IMP, VIM, SIM and NDM) had been found in 
Acinetobacter sp. The blaNDM gene is usually found flanked by two copies of the 
ISAba125 element, forming a composite transposon named Tn125 (Bonnin et al., 2012). 
The discovery of a truncated form of this composite transposon in Enterobacteriaceae 
in contrast to its entire form in A .baumannii is strongly suggestive of the role 
Acinetobacter plays in spreading blaNDM genes from its natural reservoir to 
Enterobactericeae (Bonnin et al., 2014).  
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Table 1.1 Summary of β-lactamases presents in A. baumannii (based on Ambler 
classification) 
Ambler 
Class 
Active 
Site 
Enzyme Type Subtrates Enzymes 
found in A. 
baumannii  
A Serine Extended-spectrum 
(β-lactamase) 
Benzylpenicillin, 
aminopenicillins, 
carboxypenicillins, 
ureidopenicillins, narrow-
spectrum cephalosporins, 
oxymino-β-lactams 
(cefotaxime, ceftazidime, 
ceftriaxone) and 
aztreonam 
VEB-1, PER-
1 and -2, 
TEM-92 and 
-116, SHV-
12 and CTX-
M-2 and -43 
B Metallo-β-
lactamases 
Carbapenemases Substrates of extended-
spectrum plus 
cephamycins and 
carbapenems  
IMP, VIM, 
SIM and 
NDM 
C Serine Cephalosporinases Substrates of extended-
spectrum cephamycins, 
AmpC-type 
enzymes 
D Serine Carbapenem-
hydrolyzing 
oxacillinases 
Substrates of extended-
spectrum plus 
cephamycins and 
carbapenems 
OXA-23 until 
-27, OXA-40, 
OXA-49, 
OXA-51, 
OXA-58, 
OXA-64 until 
-82, 
AmpC, ampicillin C; CTX-M-2 and -23, cefotaxime-M-2 and -23; IMP, imipenem; 
NDM-1, New Delhi metallo-β-lactamase-1; OXA, oxacillin; PER-1, Pseudomonas 
extended resistance-1; SHV-12, sulfhydryl variable-12; SIM, Seoul imipenemase; TEM-
92 and -116, Temoneira-92 and -116; VIM, Verona integron-encoded metallo-β-
lactamase. 
 
1.5.2 Non-enzymatic Mechanisms of Resistance 
 Nonenzymatic mechanisms also had a function in conferring resistance against 
carbapenem and other antibiotics in A. baumannii. These changes include changes in 
outer membrane proteins (OMPs), multidrug efflux pumps and alterations in the affinity 
or expression of specific antibiotic binding sites. As compared to other gram-negative 
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organisms, A. baumannii generally had low permeability to antibiotic due to the small 
number and size of porins in its outer membrane.  Two of these major porins has been 
implicated in carbapenem resistance, namely CarO and OprD (Dupont et al., 2005; 
Siroy et al., 2005). These porins had been shown to allow influx of carbapenem and the 
reduction in carO transcription lead to downregulation of the CarO porin system thus a 
decrease in carbapenem influx. 
  Multidrug efflux systems is also an important mechanism of resistance in A. 
baumannii, the most prominent being the resistance-nodulation-division (RND) family-
type pump AdeABC. The AdeABC pump substrate profile includes β-lactams, 
aminoglycosides, erythromycin, chloramphenicol, tetracyclines, fluoroquinolones, 
trimethoprim and ethidium bromide (Nemec et al., 2007). AdeABC is chromosomally 
encoded and has a three-component structure: AdeB forms the transmembrane 
component, AdeA forms the inner membrane fusion protein and AdeC forms the OMP. 
It is regulated by a two-component system with a sensor kinase (AdeS) and its 
associated response regulator (AdeR) (Marchand et al., 2004).  
 A. baumannii also contains genes that codes for resistance determinants specific 
to certain antibiotics. One of them is the aminoglycoside-modifying enzymes which 
structurally modify aminoglycosides, rendering them inactive (Moniri et al., 2010). The 
16S rRNA methylase ArmA which impairs aminoglycoside binding to its target site and 
confers high-level resistance to all aminoglycosides had also been detected in A. 
baumannii (Doi et al., 2007).  Other than that, mutations in the gyrA and parC genes 
had been described. These mutations result in modifications to DNA gyrase or 
topoisomerase IV which subsequently interfere with target site binding, thus conferring 
resistance to quinolones (Higgins et al., 2004). In the case of tetracycline resistance, the 
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tet(M) gene which confers ribosomal protection had been detected in A. baumannii 
(Ribera et al., 2003). 
 Resistance against polymyxin, the last resort antimicrobial agent against XDR A. 
baumannii, was shown to be mediated by the complete loss of the initial binding target, 
the lipid A component of LPS (Moffatt et al., 2010). This is due to the mutation of one 
of the first three genes of the lipid A biosynthesis pathway; lpxA, lpxC or lpxD. The 
LPS-deficient colistin-resistant strain had a less negative charge thus reduced affinity 
towards colistin. Another possible mechanism of polymyxin resistance is through 
addition of phosphoethanolamine to hepta-acylated lipid A (Beceiro et al., 2011). This 
was a result of one amino acid change in PmrB and up-regulated expression of pmrA 
and pmrB. The LPS modification also lead to colistin resistance.  
1.6 Clinical Manifestation 
1.6.1 Risk Factors for Infection  
The ability of Acinetobacter spp. to persist on environmental surfaces and 
colonize the hands of healthcare workers transiently partly explains why infections is 
highly likely among hospitalized patients with disrupted anatomical barrier i.e. 
mechanical ventilation, urinary catheterization etc. Longer duration of hospital stay 
until infection, ICU stay, emergent surgical operation, total parenteral nutrition and 
having a central venous catheter, endotracheal tube, urinary catheter or nasogastric tube 
had all been associated with increased risk for MDR A. baumannii infection (Baran et 
al., 2008). 
Other risk factors for infection include prior use of certain antibiotics, especially 
the use of carbapenem (Corbella et al., 2000). Exposure to carbapenem gives a selective 
advantage for carbapenem-resistance strains over carbapenem-susceptible A. baumannii 
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strains. Other antibiotics that had been implicated include third-generation 
cephalosporins; a case-control study had shown that the use of third generation 
cephalosporins increase the risk of A. baumannii, regardless of susceptibility towards 
imipenem (Lee et al., 2004). 
Colonization by MDR A. baumannii is also an important predisposing factor for 
subsequent infection. A study had revealed that 41% of the patient that underwent rectal 
swab screening in ICU was colonized by A. baumannii, with 71% of them acquiring the 
organism within their first week of ICU stay (Corbella et al., 1996). Clinical infections 
occurred more frequently among those who are colonized compared to those who are 
not.  
Even though it is widely accepted that Acinetobacter sp. cause infections mainly 
in the immunocompromised patients, patients with neutropenia constitutes only a 
minority of those infected (Freire et al., 2016). Hence, focus should be on avoiding 
unnecessary invasive procedures and antimicrobial stewardship to reduce the risk for 
infection with this highly resistant pathogen.  
1.6.2 Types of Infection 
1.6.2.1 Ventricular-associated Pneumonia (VAP) 
 A. baumannii is an established hospital pathogen, and its most common clinical 
manifestations are hospital-acquired pneumonia and bacteraemia. The pathogen can 
adhere to plastic and form biofilms on endotracheal tube, which would become an ideal 
nidus for its environmental transmission (Gil-Perotin et al., 2012). Intubated patient 
would become infected through aspiration. Since natural host barriers such as the cough 
reflex is compromised in mechanically ventilated patient, aspirated droplets of the 
pathogen can go directly to the alveoli and establish infection in the tissue. 
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Acinetobacter spp. accounted for 6.1% of VAP cases in the United States from 2011 to 
2012, with 55.5% to 63.5% of the tested isolates showing carbapenem resistance 
(Weiner et al., 2016). The rates of A. baumannii VAP were significantly higher in the 
South East Asian region; this was demonstrated by a study in Thailand whereby A. 
baumannii accounted for 54.3% of VAP cases with 90.2% of them being drug-resistant 
strains (Inchai et al., 2015b). It had been shown that among (VAP) patients, those 
infected with imipenem-resistance A. baumannii had longer hospital stay before VAP 
onset and higher hospital mortality rates compared to those with imipenem-susceptible 
isolates (Chang et al., 2011).  
1.6.2.2 Blood-stream Infection 
 Likewise, Acinetobacter sp. bacteraemia usually occurs in the presence of 
intravascular catheters and could also be secondary to pneumonia (Wisplinghoff et al., 
2012). From 2011 to 2014, A. baumannii represented 1.4% of the total isolates 
responsible for central line-associated bloodstream infection in the United States, with 
carbapenem-resistance rates ranging from 46.6% to 57.2% of the tested Acinetobacter 
isolates. Data from Europe showed that 2.5% of ICU-acquired bloodstream infections 
are caused by Acinetobacter sp., with carbapenem-resistant rates of 63.5% (ECDC, 
2016).  A local study had shown that the attack rate of Acinetobacter sp. blood stream 
infection was 2.77 episodes per 1000 hospital admissions (Deris et al., 2009). In term of 
mortality, one study found that there was no statistically significant difference in term 
of mortality caused by MDR A. baumannii or non-MDR A. baumannii bacteraemia 
(Chopra et al., 2013).   
1.6.2.3 Other Nosocomial Infections 
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Acinetobacter sp. accounts for 0.7% of catheter-associated urinary tract 
infections (CAUTI) in the United States from 2011 to 2014, with carbapenem-resistance 
rates 57.7% to 69% (Weiner et al., 2016). Other recognised clinical manifestations 
include meningitis (usually in the postoperative settings) (Wroblewska et al., 2004) and 
osteomyelitis. One study had shown that A. baumannii accounts for 21% of cases of 
gram-negative osteomyelitis, with 40% of them being resistant to carbapenem 
(Carvalho et al., 2012).  
1.6.2.4 Community-acquired Infections 
 Apart from nosocomial infections, community-acquired infections of 
Acinetobacter sp. had been reported especially from countries with tropical and 
subtropical climate. Most of these infections are pneumonia, and patients affected 
usually had underlying comorbidities such as diabetes, chronic obstructive pulmonary 
disease, renal disease and lifestyle risks such as heavy smoking and excessive alcohol 
consumption (Falagas et al., 2007). A. baumannii with multiple drug resistance had also 
been implicated in cases of blood stream infections among injured US military 
personnels in Iraq and Afghanistan (Center for Disease Control and Prevention, 2004). 
1.6.3 Outcomes of XDR A. baumannii Infection 
XDR A. baumannii infection has been associated with greater mortality, 
increased costs and longer hospitalization. A study in Taiwan found that patients with A. 
baumannii complex bacteraemia had 33.6% mortality rate, and those infected who are 
infected with the imipenem resistant strains having significantly higher mortality at 70% 
(Lee et al., 2014b). Another study revealed that imipenem resistance A. baumannii 
cases had prolonged duration of bacteraemia compared to those infected with imipenem 
susceptible strains (Deris et al., 2011). A systematic review also showed that patient 
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with carbapenem-resistant A. baumannii had a significantly higher risk of mortality than 
patients with carbapenem-susceptible A. baumannii, but it was also noted that the 
carbapenem-resistant group had more severe underlying medical illness and more likely 
to receive inappropriate empirical therapy (Lemos et al., 2014). Patients with 
imipenem-resistant A. baumannii isolates, regardless of colonization or infection, also 
had greater length of hospital stay and greater hospital charges after culture (Lautenbach 
et al., 2015).  
1.7 Laboratory Identification 
1.7.1 Microscopy and Culture 
Acinetobacter sp. appears as gram negative coccobacillary cells commonly 
diplococci under Gram staining. Acinetobacter sp. can be difficult to destain, thus 
maybe misidentified as either gram-negative or gram-positive cocci in direct smears of 
clinical specimens (Das et al., 1997). The organism grows well on solid media that are 
commonly used in clinical microbiology laboratories, such as sheep blood agar & 
tryptic soy agar at a 37 °C incubation temperature. After 24 hours incubation, the 
colonies are between 0.5 and 2 mm in diameter, translucent to opaque (non-pigmented), 
convex and entire. Most strains grow well on MacConkey agar and produce a faint pink 
tint. Some Acinetobacter sp. outside the A. baumannii complex may not grow on 
MacConkey agar. 
1.7.2 Presumptive Identification via Phenotypical Characteristic 
Presumptive identification of Acinetobacter sp. to the genus level can be made 
based on the lack of cytochrome oxidase activity, lack of motility and resistance to 
penicillin. Inoculation on the triple sugar ion agar usually yield an alkaline slant and a 
neutral butt, indicating that the bacteria does not utilize glucose and lactose or sucrose. 
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Bouvet et al conducted a study to identify isolates based on the first twelve discovered 
Acinetobacter genospecies delineated by DNA-DNA hybridization through phenotypic 
properties (Bouvet and Grimont, 1987). The strains were identified based on growth at 
37 °C, 41 °C and 44 °C, production of acid from glucose, gelatin hydrolysis and 
fourteen carbon sources utilization tests. However, a subsequent study using similar 
methods revealed problems differentiating A. calcoaceticus, A. baumannii, A. pittii, and 
A. nosocomialis phenotypically, thus it has been proposed to refer to these species as the 
A. calcoaceticus-A. baumannii complex (Gerner-Smidt et al., 1991). 
Even manual identification system such as the API 20NE was unable to 
correctly distinguish between A. calcoaceticus, A. baumannii, A. pittii, and A. 
nosocomialis, and it was suggested that these species were grouped together in A. 
calcoaceticus-A. baumannii complex to improve the database accuracy (Bernards et al., 
1996) The use of semi-automated system such as Vitek 2 also showed that only 76% of 
A. baumannii can be correctly identified by the system (Joyanes et al., 2001).  
1.7.3 Identification via Genotypic Methods 
Several genotypic methods have been developed to identify Acinetobacter sp. 
Methods include amplified ribosomal DNA restriction analysis (ANDRA) 
(Vaneechoutte et al., 1995), partial rpoB gene sequence analysis (Gundi et al., 2009) 
and Fourier transform infrared spectroscopy (FITR) (Sousa et al., 2014). Amplification 
and sequencing of species-specific DNA regions such as intrinsic oxacillinases i.e 
blaOXA-51-like for A. baumannii was also widely used (Turton et al., 2006b).  
Currently, matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) seems to be the most practical method for routine use 
in clinical microbiology laboratory to accurately identify A. baumannii. When specific 
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signature profiles for A. baumannii, A. nosocomialis and A. pittii was included in the 
Bruker database, MALDI-TOF MS were able to correctly differentiate between these 
three species within the A. baumannii complex (Espinal et al., 2012). A. seifertii and A. 
dijkshoorniae, the two newest member of the A. baumannii complex, had also been 
successfully identified using MALDI-TOF MS with a positive predictive value of 
99.6% (777/780) and 96.8% (302/312), respectively (Mari-Almirall et al., 2017). 
1.7.4 Antimicrobial Sensitivity Testing 
Acinetobacter sp. had been shown to be universally resistant to penicillin, 
ampicillin, and oxyimino-cephalosporinases due to the presence of intrinsic 
chromosomal AmpC betalactamase. Most strains are also resistant to chloramphenicol. 
A. baumannii is generally more resistant to antimicrobial as compared to non-A. 
baumannii strains (Seifert et al., 1993). 
Broth microdilution or disk diffusion methods can be performed for 
susceptibility testing of Acinetobacter sp. However, broth microdilution test especially 
for beta-lactams exhibited subtle growth patterns that were difficult to interpret, leading 
to major discrepancies between microdilution and disk diffusion susceptibility results 
(Swenson et al., 2004).  On the other hand, tigecycline minimum inhibitory 
concentration (MIC) was falsely high when tested via Etest compared to broth 
microdilution method (Swenson et al., 2004). Susceptibility breakpoints has not been 
published by either Clinical Laboratory Standard Institute (CLSI) or European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) for tigecycline since the 
antibiotic was not indicated for Acinetobacter infections. Nonetheless, tigecycline has 
been used for treatment of Acinetobacter infections in the wake of increasing 
antimicrobial resistance and limited therapeutic options. Based on multicentre studies, 
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Jones et al had proposed that disc diffusion zone diameter of more or equal to 16 mm be 
regarded as sensitive while zone size less or equal to 12 mm be regarded as resistant to 
tigecycline (Jones et al., 2007). 
Previously, there were different breakpoints for many of the antibiotics between 
CLSI and EUCAST. However, the considerable differences have been eliminated when 
CLSI lowered its MIC breakpoints for A. baumannii to become very similar or identical 
to those used by EUCAST. Until now, no methods to detect the presence of the widely 
prevalent OXA-type carbapenemase in A. baumannii has been validated by CLSI. 
Detection of the OXA-type enzymes mainly depends on molecular detection of the 
blaOXA genes (Woodford et al., 2006). 
1.8 Treatment of XDR A. baumannii 
1.8.1 Single Antimicrobial Therapy 
Due to the limited therapeutic options available for the treatment of XDR A. 
baumannii, there is currently no consensus on optimal antimicrobial treatment of such 
strains. Antimicrobial regime can be administered as monotherapy or combination 
therapy; the latter being preferred to prevent new emergence of resistance and improve 
treatment outcome. 
One of the most preferred agent for monotherapy treatment of XDR A. 
baumannii is polymyxin. Polymyxins are polycationic lipopeptide that act both on the 
outer and cytoplasmic membranes of bacteria leading to loss of membrane integrity. 
Polymyxin B and polymyxin E (colistin) are suitable for clinical use. The antibiotic had 
been around for around 50 years, but its usage had been revived in the last decade in the 
face of emerging multidrug resistant gram negative bacteria. In a retrospective cohort 
study, colistin therapy for multidrug resistant (MDR) A. baumannii infection 
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successfully cured 138 (81.2%) of the patients, with 20 of them receiving monotherapy 
(Falagas et al., 2010). 75% cure rate had also been achieved among patients treated with 
colistin for VAP caused by A. baumannii and P. aeruginosa susceptible only to colistin 
(Neonakis et al.). 
An inadequacy of polymyxin, especially for treatment of Acinetobacter 
pneumonia, is that it has relatively poor penetration in the lungs. Intravenous 
administration of colistin 2 million international units three times daily in critically ill 
patients results in suboptimal serum concentration and were undetectable in the 
bronchoalveolar lavage of these patients (Imberti et al., 2010). The use of inhaled 
colistin methanesulfonate was associated with eradication of MDR A. baumannii within 
14 days after the index day and shortened the duration of MDR A. baumannii recovery 
from the respiratory tract by 2 weeks (Kuo et al., 2012). Nebulized polymyxins could 
achieve very high concentrations in the lungs with reduced systemic exposure and risk 
of toxicity. However, another study had discovered that there were no significant 
differences in terms of clinical success, clinical failure and recurrence between patients 
receiving parenteral colistin only and those receiving parenteral and nebulized colistin 
(Demirdal et al., 2016). 
Unfortunately, resistance had been reported against polymyxin, albeit the rates 
were low. Polymyxin B resistance rates was 2.1% among Acinetobacter spp., however 
the rates were slightly higher among carbapenem-resistance (2.8%) and multidrug 
resistance strains (3.2%) (Gales et al., 2006).  
Another agent commonly used as monotherapy is sulbactam. Sulbactam is a 
beta-lactamase inhibitor for most bacteria, however it has direct antimicrobial activity 
against A. baumannii. The activity of sulbactam against A. baumannii is mediated by 
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inhibition of penicillin-binding proteins (PBP) PBP1 and PBP3 (Penwell et al., 2015). A 
rare pbp3 mutants which confer high level resistant against sulbactam has also been 
discovered but may cost attenuation in fitness (Penwell et al., 2015). Unfortunately, 
resistance against sulbactam had been reported; in Taiwan the resistance rate was 70% 
(Yang et al., 2010) and in Spain only 46.7% of the A. baumannii isolates were 
susceptible to sulbactam (Fernández-Cuenca et al., 2004). It is worth noting that in 
many countries, sulbactam is commercially available only in fixed dose combination 
with either ampicillin or cefoperazone. 
Tigecycline had also been used as an option for treatment of XDR A. baumannii. 
It is the first of a novel class of minocycline derivatives known as the glycylcyclines. 
The drug binds with high affinity to bacterial ribosomes and is unaffected by 
tetracycline (tet) efflux and ribosomal protection systems. However, it serum 
concentration is low and its use for treatment had been associated with increased 
mortality and non-cure rates (Prasad et al., 2012). Specifically, MDR Acinetobacter 
bacteraemia may have inferior outcomes when treated with tigecycline including worse 
survival and failure to clear bacteraemia, even if the MIC ≤ 2 µg/ml (Gordon and 
Wareham, 2009).  
As an alternative to tigecycline, minocycline has been considered as a 
therapeutic agent against MDR Acinetobacter infections. A global surveillance program 
including XDR Acinetobacter sp. strains revealed that minocycline was the most active 
tetracycline in vitro (according to the CLSI breakpoint of MIC ≤ 4 µg/ml) (Flamm et 
al., 2016). A case series of 55 patients treated with minocycline for MDR A. baumannii 
showed that more than 70% had favourable clinical response, however only three 
received monotherapies (Goff et al., 2014). 
